188 related articles for article (PubMed ID: 27467397)
1. Reducing Both Pgp Overexpression and Drug Efflux with Anti-Cancer Gold-Paclitaxel Nanoconjugates.
Li F; Zhou X; Zhou H; Jia J; Li L; Zhai S; Yan B
PLoS One; 2016; 11(7):e0160042. PubMed ID: 27467397
[TBL] [Abstract][Full Text] [Related]
2. A dual pH-sensitive liposomal system with charge-reversal and NO generation for overcoming multidrug resistance in cancer.
Chen M; Song F; Liu Y; Tian J; Liu C; Li R; Zhang Q
Nanoscale; 2019 Mar; 11(9):3814-3826. PubMed ID: 30600823
[TBL] [Abstract][Full Text] [Related]
3. Overcoming drug-resistance in lung cancer cells by paclitaxel loaded galactoxyloglucan nanoparticles.
Reshma PL; Unnikrishnan BS; Preethi GU; Syama HP; Archana MG; Remya K; Shiji R; Sreekutty J; Sreelekha TT
Int J Biol Macromol; 2019 Sep; 136():266-274. PubMed ID: 31201909
[TBL] [Abstract][Full Text] [Related]
4. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
5. Effects of Kampo medicines on MDR-1-mediated multidrug resistance in human hepatocellular carcinoma HuH-7/PTX cells.
Hyuga S; Shiraishi M; Hori A; Hyuga M; Hanawa T
Biol Pharm Bull; 2012; 35(10):1729-39. PubMed ID: 23037162
[TBL] [Abstract][Full Text] [Related]
6. Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines.
Wang Y; Yu L; Han L; Sha X; Fang X
Int J Pharm; 2007 Jun; 337(1-2):63-73. PubMed ID: 17289311
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of a Fluorescent Analogue of Paclitaxel That Selectively Binds Microtubules and Sensitively Detects Efflux by P-Glycoprotein.
Lee MM; Gao Z; Peterson BR
Angew Chem Int Ed Engl; 2017 Jun; 56(24):6927-6931. PubMed ID: 28485901
[TBL] [Abstract][Full Text] [Related]
8. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function.
Elamanchili P; McEachern C; Burt H
J Pharm Sci; 2009 Mar; 98(3):945-58. PubMed ID: 18623213
[TBL] [Abstract][Full Text] [Related]
10. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.
Yang X; Yang P; Shen J; Osaka E; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Br J Cancer; 2014 Jun; 110(12):2896-904. PubMed ID: 24853187
[TBL] [Abstract][Full Text] [Related]
11. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel controlled delivery using a pH-responsive functional-AuNP/block-copolymer vesicular nanocarrier composite system.
Liaskoni A; Angelopoulou A; Voulgari E; Popescu MT; Tsitsilianis C; Avgoustakis K
Eur J Pharm Sci; 2018 May; 117():177-186. PubMed ID: 29477643
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Ability to reverse the drug-resistance of H460 human lung cancer cells.
Gao L; Liu G; Ma J; Wang X; Wang F; Wang H; Sun J
Colloids Surf B Biointerfaces; 2014 May; 117():122-7. PubMed ID: 24632038
[TBL] [Abstract][Full Text] [Related]
14. Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines.
Han EK; Gehrke L; Tahir SK; Credo RB; Cherian SP; Sham H; Rosenberg SH; Ng S
Eur J Cancer; 2000 Aug; 36(12):1565-71. PubMed ID: 10930805
[TBL] [Abstract][Full Text] [Related]
15. A novel approach to overcome multidrug resistance: utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors.
Yoshizawa Y; Ogawara K; Kimura T; Higaki K
Eur J Pharm Sci; 2014 Oct; 62():274-80. PubMed ID: 24956463
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
Chavanpatil MD; Patil Y; Panyam J
Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
[TBL] [Abstract][Full Text] [Related]
17. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
Baek JS; Cho CW
J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
19. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance.
Ji X; Gao Y; Chen L; Zhang Z; Deng Y; Li Y
Int J Pharm; 2012 Jan; 422(1-2):390-7. PubMed ID: 22001531
[TBL] [Abstract][Full Text] [Related]
20. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
Ho EA; Soo PL; Allen C; Piquette-Miller M
J Control Release; 2007 Jan; 117(1):20-7. PubMed ID: 17113177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
